The world is changing fast and to keep up you need local knowledge with global context.
BizNews Health covers cutting-edge research, advances, opinions and debates in medicine, health and wellbeing from orthodox, complementary and alternative perspectives. We have a special focus on nutrition, fitness, longevity medicine, and prevention of non-communicable diseases – such as obesity, cancer, type 2 diabetes, heart disease and stroke, increasingly mood disorders such as depression, and dementias. We include lifestyle and travel to healthy destinations, since mind and body are integrally connected, and optimum health is not just the absence of disease, but a state of complete physical, mental, and even spiritual wellbeing.
Successful early treatment options, which should be the bedrock of any medical intervention in the treatment of Covid 19, are being ignored by our current public health messaging.
The “drug jointly developed with Ridgeback Biotherapeutics cut risk of hospitalization or death by 50% in early look at progress.”
“A study of an HIV positive 36-year-old woman showed that Covid-19 stayed in her body for 216 days and mutated rapidly,” reports Bloomberg.
Professor Colleen Aldous argues that the scientific evidence demanded by regulatory authorities as absolute proof of Ivermectin’s impact is inappropriate.
Emile Stipp, Discovery’s Chief Actuary, unpacks his finding that up to 80% of South Africans have had Covid-19 and the notion of herd immunity.
This article outlines the Food and Drug Administration’s reasons why Ivermectin should not be used to treat or prevent Covid-19.
Abir Ballan, a member of PANDA, looks at mandatory vaccination and outlines ten reasons why COVID-19 vaccination should never be mandatory.
“Roiling tensions over vaccination against Covid-19 have spilled into an unexpected arena [in the US]: lifesaving blood transfusions”, says KHN.
In this article, Marc Girardot of PANDA explores the extent and evolution of our pre-existing immunity to Covid-19.
“We are sitting in a situation where we don’t have a vaccine constraint, at least for the next two months,” said Nicholas Crisp to Bloomberg.